Patent intelligence · US
US 12351653
Pharmaceutical compositions comprising novel cyclic peptides
Pharmaceutical compositions comprising novel cyclic peptides
Patent details — US 12351653
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 8, 2025
- Expiration
- Jul 3, 2045
- Applicant
- LISATA THERAPEUTICS, INC.
- Claims
- 14
- CPC classes
- A61K, A61K38/00, A61K38/12, A61K45/06
Quick answer
US 12351653 (Pharmaceutical compositions comprising novel cyclic peptides) is held by LISATA THERAPEUTICS, INC.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LISATA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/00, A61K38/12, A61K45/06
Frequently asked questions
What is US patent 12351653?
US 12351653 (Pharmaceutical compositions comprising novel cyclic peptides) is held by LISATA THERAPEUTICS, INC.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12351653?
LISATA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12351653 expire?
Our index shows an expiration date of Jul 3, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.